Arcutis Biotherapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
ARQT$26.20+2.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and par value)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $88,398 | $53,641 |
| Restricted cash | 925 | 1,234 |
| Marketable securities | 183,463 | 355,948 |
| Trade receivables, net | 25,807 | 8,458 |
| Inventory | 13,134 | 7,514 |
| Prepaid expenses and other current assets | 18,704 | 10,611 |
| Total current assets | 330,431 | 437,406 |
| Property and equipment, net | 1,539 | 1,881 |
| Intangible assets, net | 6,438 | 7,188 |
| Operating lease right-of-use asset | 2,361 | 2,721 |
| Other assets | 596 | 78 |
| Total assets | $341,365 | $449,274 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $11,992 | $8,827 |
| Accrued liabilities | 33,941 | 28,323 |
| Operating lease liability | 735 | 657 |
| Total current liabilities | 46,668 | 37,807 |
| Operating lease liability, noncurrent | 3,382 | 4,117 |
| Long-term debt, net | 201,799 | 197,769 |
| Other long-term liabilities | 849 | — |
| Total liabilities | 252,698 | 239,693 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized; 96,787,343 and 61,052,250 shares issued at December 31, 2023 and 2022, respectively; 96,787,343 and 61,037,403 shares outstanding at December 31, 2023 and 2022, respectively | 9 | 6 |
| Additional paid-in capital | 1,070,558 | 930,425 |
| Accumulated other comprehensive income (loss) | 4 | (1,086) |
| Accumulated deficit | (981,904) | (719,764) |
| Total stockholders’ equity | 88,667 | 209,581 |
| Total liabilities and stockholders’ equity | $341,365 | $449,274 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.